메뉴 건너뛰기
The Lancet
Volumn 378, Issue 9789, 2011, Pages 376-378
New hope for immune intervention therapy in type 1 diabetes
Author keywords

[No Author keywords available]
Indexed keywords

ABATACEPT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
EID: 79960906970     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60977-X     Document Type: Note
Times cited : (8)
References (10)
  • 1
    • 79960912796 scopus 로고    scopus 로고
    • Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial
    • and the Type 1 Diabetes TrialNet Abatacept Study Group. published online June 28. DOI:10.1016/S0140-6736(11)60886-6
    • Orban T, Bundy B, Becker DJ, et al, and the Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; published online June 28. DOI:10.1016/S0140-6736(11)60886-6.
    • (2011) Lancet
    • Orban, T.1    Bundy, B.2    Becker, D.J.3
  • 2
    • 84929620911 scopus 로고    scopus 로고
    • accessed June 23, 2011
    • TrialNet. Type 1 diabetes. http://www.diabetestrialnet.org (accessed June 23, 2011).
    • Type 1 Diabetes
  • 3
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • published online June 5. DOI:10.1056/NEJMoa1104621
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; published online June 5. DOI:10.1056/NEJMoa1104621.
    • (2011) N Engl J Med
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 4
    • 77950649733 scopus 로고    scopus 로고
    • Developing combination immunotherapies for type 1 diabetes: Recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group
    • for the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group
    • Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, for the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010; 160: 176-84.
    • (2010) Clin Exp Immunol , vol.160 , pp. 176-184
    • Matthews, J.B.1    Staeva, T.P.2    Bernstein, P.L.3    Peakman, M.4    Von Herrath, M.5
  • 5
    • 70349442506 scopus 로고    scopus 로고
    • The Diabetes Control and Complications Trial: The gift that keeps giving
    • Kilpatrick ES, Rigby AS, Atkin SL. The Diabetes Control and Complications Trial: the gift that keeps giving. Nat Rev Endocrinol 2009; 5: 537-45.
    • (2009) Nat Rev Endocrinol , vol.5 , pp. 537-545
    • Kilpatrick, E.S.1    Rigby, A.S.2    Atkin, S.L.3
  • 6
    • 79955529454 scopus 로고    scopus 로고
    • Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4
    • Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600-03.
    • (2011) Science , vol.332 , pp. 600-603
    • Qureshi, O.S.1    Zheng, Y.2    Nakamura, K.3
  • 7
    • 33847617787 scopus 로고    scopus 로고
    • Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes
    • DOI 10.1111/j.1365-2249.2007.03328.x
    • Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148: 17-31. (Pubitemid 46364996)
    • (2007) Clinical and Experimental Immunology , vol.148 , Issue.1 , pp. 17-31
    • Staeva-Vieira, T.1    Peakman, M.2    Von Herrath, M.3
  • 8
    • 0037198446 scopus 로고    scopus 로고
    • Can we change the course of beta-cell destruction in type 1 diabetes?
    • DOI 10.1056/NEJM200205303462211
    • Gale EA. Can we change the course of beta-cell destruction in type 1 diabetes? N Engl J Med 2002; 346: 1740-42. (Pubitemid 34547489)
    • (2002) New England Journal of Medicine , vol.346 , Issue.22 , pp. 1740-1742
    • Gale, E.A.M.1
  • 9
    • 75649134941 scopus 로고    scopus 로고
    • Surrogate end points in the design of immunotherapy trials: Emerging lessons from type 1 diabetes
    • Roep BO, Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 2010; 10: 145-52.
    • (2010) Nat Rev Immunol , vol.10 , pp. 145-152
    • Roep, B.O.1    Peakman, M.2
  • 10
    • 79956061593 scopus 로고    scopus 로고
    • 1Cand mean glucose in patients with type 1 diabetes: Analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial
    • Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group
    • 1C and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care 2011; 34: 540-44.
    • (2011) Diabetes Care , vol.34 , pp. 540-544

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.